Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Delta plus variant reclassified as 'variant of concern', experts sanguine for now

Wed, 23rd Jun 2021 10:47

(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".
Nevertheless, several experts believe it is too soon to draw any conclusions.

The ministry said that the new variant, also known as AY.1, spreads with greater ease, binds more easily to lung cells and might be resistant to monoclonal antibody therapies.

AY.1 was first detected in April in India and is now present in three states - Maharashtra, Kerala and Madhya Pradesh - with roughly 40 samples having been collected.

It had also been found in nine other countries, Portugal, China, Japan, Nepal, Poland, Russia, Switzerland, UK and US.

For a Covid-19 variant to be considered a "variant of concern", it must meet at least one of four conditions: easier transmission, more severe illness, reduced neutralisation by antibodies or lower effectiveness of treatments and vaccines.

Yet in remarks to the BBC, Dr Gagandeep Kang, a virologist and fellow of the Royal Society of London, said "there is now data yet to support the variant of concern claim".

"You need biological and clinical information in order to consider whether it is truly a variant of concern."

Dr Jeremy Kamil, a virologist at Louisiana State University, was of much the same view, telling the BBC that: "we don't have much reason to believe this is any more dangerous than the original Delta."

"I would keep calm. I don't think India or anyone else in the world has released or accumulated enough data to distinguish the risk from the so-called Delta plus as being more dangerous or concerning than the original Delta variant."

The Delta plus variant includes one additional mutation on the so-called spike protein called K417N.

Related Shares

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.